Finding/VBG
Genetic/JJ
Risk/NN
Factors/NNS
of/IN
Gestational/JJ
Diabetes/NNS
./.
====================
Gestational/JJ
diabetes/NNS
mellitus/NN
(/(
GDM/NN
)/)
is/VBZ
a/DT
complex/NN
metabolic/JJ
disorder/NN
of/IN
pregnancy/NN
that/DT
is/VBZ
suspected/VBN
to/TO
have/VB
a/DT
strong/JJ
genetic/JJ
predisposition/NN
./.
====================
It/PRP
is/VBZ
associated/VBN
with/IN
poor/JJ
perinatal/JJ
outcome/NN
,/,
and/CC
both/CC
GDM/NN
women/NNS
and/CC
their/PRP$
offspring/VBG
are/VBP
at/IN
increased/VBN
risk/NN
of/IN
future/JJ
development/NN
of/IN
type/NN
2/CD
diabetes/NNS
mellitus/NN
(/(
T2DM/NN
)/)
./.
====================
During/IN
the/DT
past/NN
several/JJ
years/NNS
,/,
there/EX
has/VBZ
been/VBN
progress/RB
in/IN
finding/NN
the/DT
genetic/JJ
risk/NN
factors/NNS
of/IN
GDM/NN
in/IN
relation/NN
to/TO
T2DM/NN
./.
====================
Some/DT
of/IN
the/DT
genetic/JJ
variants/NNS
that/WDT
were/VBD
proven/VBN
to/TO
be/VB
significantly/RB
associated/VBN
with/IN
T2DM/NN
are/VBP
also/RB
genetic/JJ
risk/NN
factors/NNS
of/IN
GDM/NN
./.
====================
Recently/RB
,/,
a/DT
genome-wide/JJ
association/NN
study/NN
of/IN
GDM/NN
was/VBD
performed/VBN
and/CC
reported/VBD
that/IN
genetic/JJ
variants/NNS
in/IN
CDKAL1/NN
and/CC
MTNR1B/NN
were/VBD
associated/VBN
with/IN
GDM/NN
at/IN
a/DT
genome-wide/JJ
significance/NN
level/NN
./.
====================
Current/JJ
investigations/NNS
using/VBG
next-generation/JJ
sequencing/NN
will/MD
improve/VB
our/PRP$
insight/NN
into/IN
the/DT
pathophysiology/NN
of/IN
GDM/NN
./.
====================
It/PRP
would/MD
be/VB
important/JJ
to/TO
know/VB
whether/IN
genetic/JJ
information/NN
revealed/VBD
from/IN
these/DT
studies/NNS
could/MD
improve/VB
our/PRP$
prediction/NN
of/IN
GDM/NN
and/CC
the/DT
future/JJ
development/NN
of/IN
T2DM/NN
./.
====================
We/PRP
hope/VBP
further/RBR
research/NN
on/IN
the/DT
genetics/NNS
of/IN
GDM/NN
would/MD
ultimately/RB
lead/VBP
us/PRP
to/TO
personalized/VBN
genomic/JJ
medicine/NN
and/CC
improved/VBD
patient/NN
care/JJ
./.
====================
Gestational/JJ
diabetes/NNS
mellitus/NN
(/(
GDM/NN
)/)
is/VBZ
defined/VBN
as/IN
abnormal/JJ
glucose/NN
tolerance/NN
that/IN
is/VBZ
first/JJ
identified/VBD
or/CC
diagnosed/VBN
during/IN
pregnancy/NN
[/(
1/CD
]/)
./.
====================
It/PRP
is/VBZ
estimated/VBN
that/DT
approximately/RB
2/CD
%/NN
to/TO
5/CD
%/NN
of/IN
all/DT
pregnancies/NNS
in/IN
Korean/JJ
women/NNS
are/VBP
complicated/VBN
by/IN
GDM/NN
[/(
2/CD
]/)
./.
====================
The/DT
clinical/JJ
significance/NN
of/IN
GDM/NN
is/VBZ
that/DT
it/PRP
increases/VBZ
the/DT
risk/NN
of/IN
adverse/JJ
pregnancy/NN
outcomes/NNS
[/(
3/CD
]/)
./.
====================
In/IN
a/DT
recent/JJ
large-scale/JJ
multinational/JJ
prospective/JJ
study/NN
,/,
increased/VBD
maternal/JJ
glucose/NN
concentration/NN
during/IN
pregnancy/NN
was/VBD
significantly/RB
associated/VBN
with/IN
increased/VBN
neonatal/JJ
birth/IN
weight/NN
,/,
primary/JJ
cesarean/JJ
delivery/NN
,/,
neonatal/JJ
hypoglycemia/NN
,/,
and/CC
increased/VBD
placental/JJ
C-peptide/NN
levels/NNS
[/(
4/CD
]/)
./.
====================
After/IN
parturition/NN
,/,
about/RB
15/CD
%/NN
of/IN
GDM/NN
women/NNS
had/VBD
persistent/JJ
diabetes/NNS
at/IN
an/DT
early/JJ
postpartum/NN
period/NN
of/IN
2/CD
months/NNS
[/(
5/CD
]/)
./.
====================
GDM/NN
is/VBZ
also/RB
reported/VBD
to/TO
recur/VB
at/IN
a/DT
frequency/NN
of/IN
45/CD
%/NN
in/IN
subsequent/JJ
pregnancies/NNS
[/(
6/CD
]/)
./.
====================
Women/NNS
with/IN
a/DT
previous/JJ
history/JJ
of/IN
GDM/NN
are/VBP
at/IN
increased/VBN
risk/NN
of/IN
future/JJ
development/NN
of/IN
type/NN
2/CD
diabetes/NNS
mellitus/NN
(/(
T2DM/NN
)/)
./.
====================
The/DT
risk/NN
of/IN
T2DM/NN
is/VBZ
3.5/CD
times/NNS
greater/JJR
in/IN
women/NNS
with/IN
a/DT
history/JJ
of/IN
GDM/NN
compared/VBN
to/TO
the/DT
general/JJ
population/NN
in/IN
Koreans/NNS
[/(
7/CD
]/)
./.
====================
In/IN
addition/NN
,/,
offspring/VBG
of/IN
GDM/NN
women/NNS
are/VBP
also/RB
at/IN
risk/NN
of/IN
developing/VBG
obesity/NN
and/CC
T2DM/NN
[/(
8/CD
]/)
./.
====================
The/DT
incidence/NN
of/IN
GDM/NN
is/VBZ
expected/VBN
to/TO
rise/VB
,/,
as/IN
it/PRP
will/MD
parallel/NN
the/DT
increasing/VBG
rate/NN
of/IN
obesity/NN
and/CC
T2DM/NN
./.
====================
Furthermore/RB
,/,
the/DT
recent/JJ
recommendation/NN
from/IN
the/DT
International/JJ
Association/NN
of/IN
Diabetes/NNS
and/CC
Pregnancy/NN
Study/NN
Group/NN
has/VBZ
lowered/VBN
the/DT
diagnostic/JJ
threshold/JJ
of/IN
GDM/NN
and/CC
is/VBZ
expected/VBN
to/TO
increase/VB
the/DT
incidence/NN
of/IN
GDM/NN
[/(
9/CD
]/)
./.
====================
GDM/NN
is/VBZ
thought/VBN
to/TO
have/VB
strong/JJ
heritability/NN
./.
====================
GDM/NN
women/NNS
have/VBP
an/DT
increased/VBN
positive/JJ
family/NN
history/NN
of/IN
T2DM/NN
./.
====================
Compared/VBN
to/TO
pregnant/JJ
women/NNS
with/IN
normal/JJ
glucose/NN
tolerance/NN
,/,
GDM/NN
women/NNS
have/VBP
a/DT
significantly/RB
greater/JJR
parental/JJ
history/JJ
of/IN
T2DM/NN
(/(
13.2/CD
%/NN
vs./CC
30.1/CD
%/NN
,/,
p/NN
</JJR
0.001/CD
)/)
[/(
10/CD
]/)
./.
====================
In/IN
addition/NN
,/,
both/CC
GDM/NN
women/NNS
and/CC
their/PRP$
offspring/VBG
are/VBP
at/IN
increased/VBN
risk/NN
of/IN
future/JJ
development/NN
of/IN
T2DM/NN
./.
====================
The/DT
heritability/NN
estimate/NN
of/IN
T2DM/NN
was/VBD
reported/VBN
to/TO
be/VB
quite/RB
high/JJ
(/(
h2/NN
=/JJ
0.69/CD
)/)
in/IN
a/DT
recent/JJ
study/NN
performed/VBD
in/IN
Europeans/NNS
[/(
11/CD
]/)
./.
====================
These/DT
findings/NNS
are/VBP
indirect/JJ
evidence/NN
that/IN
GDM/NN
has/VBZ
familial/JJ
tendency/NN
./.
====================
However/RB
,/,
there/EX
is/VBZ
no/DT
study/NN
that/IN
has/VBZ
specifically/RB
evaluated/VBD
the/DT
heritability/NN
of/IN
GDM/NN
using/VBG
familial/JJ
clustering/NN
or/CC
twins/NNS
[/(
12/CD
]/)
./.
====================
It/PRP
would/MD
be/VB
important/JJ
to/TO
estimate/VB
the/DT
heritability/NN
of/IN
GDM/NN
and/CC
compare/VBP
it/PRP
with/IN
that/DT
of/IN
T2DM/NN
in/IN
women/NNS
./.
====================
During/IN
normal/JJ
pregnancy/NN
,/,
women/NNS
experience/VBP
increased/VBD
adiposity/NN
and/CC
weight/NN
gain/NN
,/,
which/WDT
begin/VBP
near/JJ
mid-pregnancy/NN
and/CC
progress/VBP
throughout/IN
the/DT
third/JJ
trimester/NN
[/(
13/CD
]/)
./.
====================
In/IN
this/DT
period/NN
,/,
insulin/NN
resistance/NN
ensues/VBZ
as/IN
a/DT
consequence/NN
of/IN
multiple/JJ
factors/NNS
,/,
including/VBG
increased/VBD
production/NN
of/IN
placental/JJ
growth/NN
hormone/NN
,/,
estrogen/NN
,/,
and/CC
tumor/NN
necrosis/NN
factor/NN
α/RB
[/(
14/CD
,/,
15/CD
]/)
./.
====================
Pregnant/JJ
women/NNS
with/IN
normal/JJ
glucose/NN
tolerance/NN
can/MD
increase/VB
their/PRP$
β-cell/JJ
insulin/NN
secretion/NN
in/IN
response/NN
to/TO
this/DT
increased/VBN
insulin/NN
resistance/NN
during/IN
pregnancy/NN
./.
====================
Although/IN
the/DT
mechanism/NN
of/IN
increased/VBN
β-cell/RB
insulin/NN
secretion/NN
during/IN
pregnancy/NN
is/VBZ
not/RB
fully/RB
understood/VBN
,/,
it/PRP
is/VBZ
reported/VBN
that/IN
prolactin/NN
,/,
which/WDT
increases/VBZ
during/IN
pregnancy/NN
,/,
can/MD
repress/VB
islet/NN
menin/NN
levels/NNS
and/CC
stimulate/VBP
β-cell/JJ
proliferation/NN
in/IN
mice/NNS
[/(
16/CD
]/)
./.
====================
In/IN
addition/NN
,/,
recent/JJ
reports/NNS
suggest/VBP
that/IN
β-cell/JJ
serotonin/NN
signaling/NN
is/VBZ
also/RB
a/DT
major/JJ
determinant/NN
of/IN
β-cell/JJ
mass/NN
during/IN
pregnancy/NN
[/(
17/CD
]/)
./.
====================
It/PRP
has/VBZ
been/VBN
suggested/VBN
from/IN
several/JJ
clinical/JJ
studies/NNS
that/IN
GDM/NN
women/NNS
have/VBP
limited/VBN
insulin/NN
secretion/NN
capacity/NN
that/DT
can/MD
not/RB
compensate/VB
for/IN
the/DT
increased/VBN
insulin/NN
resistance/NN
[/(
13/CD
]/)
./.
====================
Similar/JJ
to/TO
GDM/NN
,/,
T2DM/NN
is/VBZ
also/RB
characterized/VBD
by/IN
relative/JJ
deficiency/NN
in/IN
insulin/NN
secretion/NN
in/IN
the/DT
face/NN
of/IN
increased/VBN
insulin/NN
resistance/NN
./.
====================
Various/JJ
factors/NNS
,/,
including/VBG
increased/VBD
age/NN
,/,
obesity/NN
,/,
high-fat/JJ
diet/VBP
,/,
and/CC
sedentary/JJ
lifestyle/JJ
,/,
can/MD
induce/VB
insulin/NN
resistance/NN
,/,
and/CC
those/DT
who/WP
do/VBP
not/RB
have/VB
sufficient/JJ
β-cell/NN
insulin/NN
secretory/JJ
capacity/NN
are/VBP
more/RBR
likely/JJ
to/TO
develop/VB
T2DM/NN
[/(
13/CD
]/)
./.
====================
Therefore/RB
,/,
it/PRP
is/VBZ
said/VBN
that/DT
a/DT
large/JJ
proportion/NN
of/IN
GDM/NN
women/NNS
are/VBP
experiencing/VBG
future/JJ
T2DM/NN
in/IN
advance/NN
./.
====================
Based/VBN
on/IN
the/DT
findings/NNS
that/IN
GDM/NN
women/NNS
are/VBP
at/IN
high/JJ
risk/NN
of/IN
T2DM/NN
and/CC
both/CC
GDM/NN
and/CC
T2DM/NN
share/VBP
similar/JJ
pathophysiologies/NNS
,/,
it/PRP
is/VBZ
reasonable/JJ
to/TO
assume/VB
that/DT
they/PRP
might/MD
also/RB
share/VBP
similar/JJ
genetic/JJ
risk/NN
factors/NNS
./.
====================
Soon/RB
after/IN
the/DT
initial/JJ
reports/NNS
of/IN
T2DM/NN
genome-wide/NN
association/NN
(/(
GWA/NN
)/)
studies/NNS
[/(
18-21/CD
]/)
,/,
several/JJ
studies/NNS
investigated/VBD
whether/IN
genetic/JJ
variants/NNS
that/IN
were/VBD
identified/VBN
through/IN
GWA/NN
studies/NNS
of/IN
T2DM/NN
were/VBD
also/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
GDM/NN
[/(
22/CD
,/,
23/CD
]/)
./.
====================
Cho/NN
et/FW
al/JJ
./.
====================
[/(
22/CD
]/)
genotyped/VBD
variants/NNS
in/IN
or/CC
near/JJ
CDKAL1/NN
,/,
CDKN2A/2B/NN
,/,
FTO/NN
,/,
HHEX/NN
,/,
IGF2BP2/NN
,/,
SLC30A8/NN
,/,
TCF7L2/NN
,/,
KCNJ11/NN
,/,
and/CC
PPARG/NN
in/IN
869/CD
GDM/NN
women/NNS
and/CC
632/CD
carefully/RB
selected/VBN
nondiabetic/JJ
control/NN
subjects/NNS
./.
====================
They/PRP
found/VBD
that/IN
genetic/JJ
variants/NNS
in/IN
CDKAL1/NN
and/CC
CDKN2A/2B/NN
were/VBD
highly/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
GDM/NN
(/(
p/NN
</JJR
1/CD
×/NN
10-6/CD
)/)
./.
====================
In/IN
addition/NN
,/,
variants/NNS
in/IN
HHEX/NN
,/,
IGF2BP2/NN
,/,
SLC30A8/NN
,/,
and/CC
TCF7L2/NN
were/VBD
all/DT
nominally/RB
associated/VBN
with/IN
GDM/NN
(/(
p/NN
</JJR
0.05/CD
)/)
./.
====================
Among/IN
a/DT
total/JJ
of/IN
18/CD
genetic/JJ
variants/NNS
studied/VBD
,/,
9/CD
reached/VBD
a/DT
nominal/JJ
significance/NN
level/NN
(/(
p/NN
</JJR
0.05/CD
)/)
./.
====================
In/IN
Fig/NN
./.
====================
1/CD
,/,
the/DT
risk/NN
allele/NN
frequency/NN
as/IN
well/RB
as/IN
the/DT
odds/NNS
ratios/NNS
of/IN
known/JJ
T2DM/NN
variants/NNS
are/VBP
compared/VBN
among/IN
a/DT
control/JJ
group/NN
(/(
n/NN
=/JJ
632/CD
,/,
men/NNS
:/:
women/NNS
=/JJ
287/CD
:/:
345/CD
)/)
,/,
T2DM/NN
group/NN
(/(
n/NN
=/JJ
761/CD
,/,
men/NNS
:/:
women/NNS
=/JJ
354/CD
:/:
407/CD
)/)
,/,
and/CC
GDM/NN
group/NN
(/(
n/NN
=/JJ
869/CD
)/)
in/IN
Koreans/NNS
[/(
22/CD
,/,
24/CD
]/)
./.
====================
For/IN
most/JJS
of/IN
the/DT
variants/NNS
,/,
there/EX
was/VBD
an/DT
increasing/VBG
trend/NN
of/IN
risk/NN
allele/NN
frequencies/NNS
from/IN
control/JJ
to/TO
T2DM/NN
and/CC
from/IN
T2DM/NN
to/TO
GDM/NN
./.
====================
Lauenborg/NN
et/FW
al/JJ
./.
====================
[/(
23/CD
]/)
also/RB
found/VBD
that/IN
variants/NNS
in/IN
TCF7L2/NN
,/,
CDKAL1/NN
,/,
and/CC
TCF2/NN
were/VBD
significantly/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
GDM/NN
in/IN
Europeans/NNS
,/,
consisting/VBG
of/IN
283/CD
GDM/NN
women/NNS
and/CC
2,446/CD
glucose-tolerant/JJ
control/NN
women/NNS
./.
====================
Variants/NNS
in/IN
KCNQ1/NN
,/,
which/WDT
were/VBD
first/RB
identified/VBD
in/IN
an/DT
East/JJ
Asian/JJ
T2DM/NN
GWA/NN
study/NN
,/,
were/VBD
also/RB
significantly/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
GDM/NN
in/IN
Koreans/NNS
(/(
p/NN
</JJR
0.05/CD
)/)
[/(
25/CD
]/)
./.
====================
Recently/RB
,/,
it/PRP
was/VBD
reported/VBN
that/IN
TPH1/NN
and/CC
HTR2B/NN
play/VBP
a/DT
crucial/JJ
role/NN
in/IN
regulating/VBG
pancreatic/JJ
β-cell/NN
mass/NN
during/IN
pregnancy/NN
in/IN
a/DT
mouse/NN
model/NN
and/CC
that/IN
their/PRP$
genetic/JJ
alterations/NNS
could/MD
result/VB
in/IN
GDM/NN
[/(
17/CD
]/)
./.
====================
A/DT
total/JJ
6/CD
genetic/JJ
variants/NNS
in/IN
HTR2B/NN
and/CC
11/CD
variants/NNS
in/IN
TPH1/NN
were/VBD
identified/VBN
and/CC
genotyped/VBD
in/IN
Korean/JJ
GDM/NN
women/NNS
and/CC
control/NN
subjects/NNS
[/(
26/CD
]/)
./.
====================
Although/IN
there/EX
were/VBD
no/DT
significant/JJ
associations/NNS
of/IN
these/DT
variants/NNS
with/IN
the/DT
risk/NN
of/IN
GDM/NN
,/,
they/PRP
were/VBD
associated/VBN
with/IN
measures/NNS
of/IN
obesity/NN
and/CC
weight/NN
gain/NN
during/IN
pregnancy/NN
[/(
26/CD
]/)
./.
====================
Following/VBG
these/DT
candidate/NN
approach/NN
studies/NNS
was/VBD
a/DT
two-staged/JJ
GWA/NN
study/NN
that/IN
was/VBD
performed/VBN
in/IN
Korean/JJ
GDM/NN
women/NNS
[/(
27/CD
]/)
./.
====================
A/DT
total/JJ
of/IN
468/CD
GDM/NN
women/NNS
and/CC
1,242/CD
nondiabetic/JJ
control/NN
women/NNS
were/VBD
genotyped/VBN
using/VBG
Affymetrix/JJ
Genome-Wide/NN
Human/JJ
SNP/NN
Array/NN
5.0/CD
./.
====================
Variants/NNS
that/DT
passed/VBN
the/DT
prespecified/VBN
p-value/NN
threshold/NN
in/IN
the/DT
stage/NN
1/CD
genome/NN
scan/NN
were/VBD
further/RB
genotyped/VBD
in/IN
931/CD
GDM/NN
women/NNS
and/CC
783/CD
nondiabetic/JJ
control/NN
women/NNS
./.
====================
Two/CD
variants/NNS
,/,
one/CD
located/JJ
in/IN
an/DT
intron/NN
of/IN
CDKAL1/NN
(/(
rs7754840/CD
)/)
and/CC
one/CD
near/JJ
MTNR1B/NN
(/(
rs10830962/NN
)/)
,/,
were/VBD
associated/VBN
with/IN
a/DT
risk/NN
of/IN
GDM/NN
at/IN
a/DT
genome-wide/JJ
significance/NN
level/NN
(/(
p/NN
=/JJ
6.65/CD
×/CD
10-16/CD
and/CC
p/NN
=/JJ
2.49/CD
×/CD
10-13/CD
,/,
respectively/RB
)/)
./.
====================
This/DT
was/VBD
the/DT
first/JJ
GWA/NN
study/NN
investigating/VBG
the/DT
genetic/JJ
risk/NN
factors/NNS
of/IN
GDM/NN
./.
====================
Although/IN
variants/NNS
in/IN
MTNR1B/NN
have/VBP
been/VBN
previously/RB
reported/VBD
to/TO
be/VB
associated/VBN
with/IN
increased/VBN
fasting/JJ
glucose/NN
levels/NNS
,/,
the/DT
study/NN
was/VBD
the/DT
first/JJ
to/TO
report/VB
that/IN
MTNR1B/NN
variants/NNS
are/VBP
associated/VBN
with/IN
GDM/NN
at/IN
a/DT
genome-wide/JJ
significance/NN
level/NN
./.
====================
One/CD
of/IN
the/DT
limitations/NNS
was/VBD
that/DT
it/PRP
was/VBD
not/RB
sufficiently/RB
powered/JJ
to/TO
find/VB
truly/RB
novel/JJ
genetic/JJ
variants/NNS
that/WDT
were/VBD
only/RB
specific/JJ
in/IN
GDM/NN
./.
====================
It/PRP
should/MD
be/VB
noted/VBN
that/IN
current/JJ
GWA/NN
and/CC
GWA/NN
meta-analysis/NN
performed/VBN
in/IN
T2DM/NN
recruits/VBZ
more/RBR
than/IN
100,000/CD
cases/NNS
and/CC
controls/VBZ
[/(
28/CD
]/)
./.
====================
One/CD
of/IN
the/DT
interesting/JJ
findings/NNS
was/VBD
that/DT
genetic/JJ
variants/NNS
of/IN
T2DM/NN
were/VBD
enriched/VBN
in/IN
GDM/NN
subjects/NNS
./.
====================
Among/IN
the/DT
34/CD
confirmed/VBD
T2DM/NN
genetic/JJ
variants/NNS
,/,
8/CD
were/VBD
associated/VBN
with/IN
a/DT
risk/NN
of/IN
GDM/NN
[/(
27/CD
]/)
./.
====================
In/IN
addition/NN
,/,
when/WRB
the/DT
β-coefficients/NNS
(/(
or/CC
odds/NNS
ratio/NN
)/)
of/IN
the/DT
variants/NNS
derived/VBN
from/IN
the/DT
logistic/JJ
regression/NN
were/VBD
compared/VBN
between/IN
GDM/NN
and/CC
T2DM/NN
,/,
there/EX
was/VBD
a/DT
significant/JJ
positive/JJ
correlation/NN
of/IN
β-coefficients/NNS
between/IN
the/DT
two/CD
[/(
27/CD
]/)
./.
====================
These/DT
findings/NNS
suggest/VBP
that/IN
GDM/NN
and/CC
T2DM/NN
might/MD
share/VB
similar/JJ
genetic/JJ
backgrounds/NNS
,/,
at/IN
least/JJS
in/IN
part/NN
./.
====================
GWA/NN
studies/NNS
have/VBP
opened/VBN
a/DT
new/JJ
era/NN
in/IN
diabetes/NNS
research/NN
./.
====================
Our/PRP$
knowledge/NN
on/IN
the/DT
genetic/JJ
predisposition/NN
of/IN
GDM/NN
as/IN
well/RB
as/IN
T2DM/NN
is/VBZ
expected/VBN
to/TO
increase/VB
even/RB
faster/JJR
as/IN
next-generation/JJ
sequencing/NN
technology/NN
is/VBZ
applied/VBN
to/TO
this/DT
field/NN
./.
====================
There/EX
should/MD
be/VB
even/RB
larger/JJR
GWA/NN
studies/NNS
on/IN
GDM/NN
,/,
and/CC
GWA/NN
meta-analyses/NNS
should/MD
be/VB
available/JJ
./.
====================
In/IN
this/DT
way/NN
,/,
we/PRP
could/MD
find/VB
variants/NNS
that/WDT
have/VBP
smaller/JJR
effect/NN
sizes/NNS
but/CC
are/VBP
more/RBR
specific/JJ
to/TO
GDM/NN
than/IN
T2DM/NN
./.
====================
In/IN
order/NN
to/TO
understand/VB
the/DT
genetic/JJ
determinants/NNS
of/IN
glucose/NN
and/CC
insulin/NN
concentration/NN
during/IN
pregnancy/NN
,/,
genetic/JJ
associations/NNS
regarding/VBG
these/DT
quantitative/JJ
traits/VBZ
should/MD
be/VB
investigated/VBN
./.
====================
A/DT
fast/JJ
way/NN
is/VBZ
to/TO
see/VB
whether/IN
genetic/JJ
variants/NNS
that/IN
are/VBP
known/VBN
to/TO
affect/VB
glucose/NN
or/CC
insulin/NN
concentration/NN
in/IN
the/DT
normal/JJ
population/NN
also/RB
affect/VB
glucose/NN
or/CC
insulin/NN
concentration/NN
during/IN
pregnancy/NN
[/(
29/CD
]/)
./.
====================
In/IN
addition/NN
,/,
a/DT
GWA/NN
study/NN
on/IN
glucose/NN
or/CC
insulin/NN
concentration/NN
during/IN
pregnancy/NN
should/MD
also/RB
be/VB
helpful/JJ
./.
====================
In/IN
this/DT
way/NN
,/,
we/PRP
would/MD
be/VB
able/JJ
to/TO
better/RBR
understand/VB
the/DT
pathophysiology/NN
of/IN
GDM/NN
./.
====================
By/IN
definition/NN
,/,
GDM/NN
encompasses/VBZ
women/NNS
with/IN
pre-exiting/VBG
T2DM/NN
,/,
maturity/NN
onset/NN
diabetes/NNS
of/IN
the/DT
young/JJ
(/(
MODY/NN
)/)
,/,
or/CC
even/RB
type/NN
1/CD
diabetes/VBZ
patients/NNS
that/WDT
were/VBD
not/RB
diagnosed/VBN
previously/RB
./.
====================
It/PRP
would/MD
be/VB
important/JJ
to/TO
know/VB
the/DT
proportion/NN
of/IN
MODY/NN
patients/NNS
that/WDT
constitute/VBP
GDM/NN
./.
====================
In/IN
particular/JJ
,/,
about/RB
15/CD
%/NN
of/IN
GDM/NN
patients/NNS
remain/VBP
diabetic/JJ
at/IN
early/JJ
postpartum/NN
periods/NNS
,/,
and/CC
a/DT
significant/JJ
portion/NN
of/IN
these/DT
subjects/NNS
might/MD
fall/DT
into/IN
the/DT
category/NN
of/IN
MODY/NN
./.
====================
The/DT
contribution/NN
of/IN
genetic/JJ
variants/NNS
known/VBN
to/TO
cause/VB
MODY/NN
,/,
such/JJ
as/IN
GCK/NN
and/CC
HNF1A/NN
,/,
in/IN
GDM/NN
has/VBZ
been/VBN
reviewed/VBN
in/IN
recent/JJ
literature/NN
[/(
30/CD
]/)
./.
====================
However/RB
,/,
whole-exome/WP$
sequencing/NN
will/MD
provide/VB
us/PRP
with/IN
better/RBR
bird/NN
's/POS
eye/NN
view/NN
on/IN
the/DT
contribution/NN
of/IN
MODY/NN
genes/NNS
in/IN
GDM/NN
./.
====================
In/IN
addition/NN
,/,
it/PRP
might/MD
be/VB
able/JJ
to/TO
find/VB
novel/JJ
MODY/NN
genes/NNS
in/IN
those/DT
who/WP
have/VBP
persistent/JJ
diabetes/NNS
after/IN
GDM/NN
pregnancy/NN
and/CC
also/RB
have/VBP
a/DT
strong/JJ
family/NN
history/NN
of/IN
diabetes/NNS
./.
====================
One/CD
of/IN
the/DT
first/JJ
steps/NNS
in/IN
translating/VBG
the/DT
genetic/JJ
information/NN
into/IN
clinical/JJ
practice/NN
would/MD
be/VB
to/TO
predict/VB
the/DT
future/JJ
development/NN
of/IN
T2DM/NN
in/IN
GDM/NN
women/NNS
./.
====================
GDM/NN
women/NNS
are/VBP
at/IN
particularly/RB
high/JJ
risk/NN
of/IN
developing/VBG
T2DM/NN
and/CC
require/VB
preventive/JJ
measures/NNS
and/CC
early/JJ
screening/NN
of/IN
T2DM/NN
./.
====================
Genetic/JJ
information/NN
might/MD
improve/VB
our/PRP$
prediction/NN
of/IN
T2DM/NN
in/IN
women/NNS
with/IN
a/DT
history/JJ
of/IN
GDM/NN
./.
====================
This/DT
is/VBZ
an/DT
area/NN
of/IN
active/JJ
research/NN
[/(
31/CD
,/,
32/CD
]/)
,/,
and/CC
we/PRP
are/VBP
looking/VBG
forward/IN
to/TO
studies/NNS
that/IN
use/VBP
genotype/NN
risk/NN
scores/NNS
in/IN
predicting/VBG
T2DM/NN
in/IN
GDM/NN
women/NNS
./.
====================
A/DT
similar/JJ
approach/NN
could/MD
also/RB
be/VB
applied/VBN
in/IN
predicting/VBG
GDM/NN
,/,
as/IN
more/RBR
genetic/JJ
variants/NNS
associated/VBN
with/IN
GDM/NN
are/VBP
expected/VBN
to/TO
be/VB
revealed/VBN
./.
====================
The/DT
functional/JJ
consequences/NNS
of/IN
the/DT
current/JJ
common/JJ
genetic/JJ
variants/NNS
identified/VBD
through/IN
GWA/NN
studies/NNS
of/IN
GDM/NN
are/VBP
not/RB
well/RB
understood/VBN
yet/RB
./.
====================
It/PRP
is/VBZ
not/RB
known/VBN
whether/IN
they/PRP
are/VBP
markers/NNS
in/IN
linkage/NN
disequilibrium/NN
with/IN
nearby/JJ
causal/JJ
variants/NNS
or/CC
whether/IN
they/PRP
have/VBP
unknown/JJ
but/CC
relevant/JJ
functional/JJ
roles/NNS
./.
====================
Next-generation/NN
sequencing/NN
might/MD
give/VB
answers/NNS
to/TO
these/DT
questions/NNS
,/,
but/CC
a/DT
huge/JJ
number/NN
of/IN
samples/NNS
and/CC
much/RB
effort/NN
will/MD
be/VB
required/VBN
./.
====================
GDM/NN
women/NNS
are/VBP
at/IN
increased/VBN
risk/NN
of/IN
developing/VBG
T2DM/NN
and/CC
have/VBP
familial/JJ
clustering/NN
of/IN
T2DM/NN
./.
====================
A/DT
common/JJ
pathophysiology/NN
that/DT
is/VBZ
shared/VBN
by/IN
GDM/NN
and/CC
T2DM/NN
is/VBZ
impaired/JJ
compensatory/JJ
increase/VBP
in/IN
insulin/NN
secretion/NN
to/TO
overcome/VB
the/DT
increased/VBN
insulin/NN
resistance/NN
./.
====================
The/DT
GWA/NN
study/NN
of/IN
GDM/NN
enabled/VBD
us/PRP
to/TO
investigate/VB
the/DT
common/JJ
genetic/JJ
risk/NN
factors/NNS
of/IN
GDM/NN
,/,
and/CC
it/PRP
revealed/VBD
that/IN
GDM/NN
and/CC
T2DM/NN
share/VBP
similar/JJ
genetic/JJ
backgrounds/NNS
,/,
at/IN
least/JJS
in/IN
part/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
Although/IN
this/DT
information/NN
has/VBZ
significantly/RB
improved/VBN
our/PRP$
insight/NN
in/IN
the/DT
pathogenesis/NN
of/IN
GDM/NN
,/,
there/EX
are/VBP
more/RBR
unanswered/JJ
questions/NNS
remaining/VBG
that/DT
should/MD
be/VB
explicitly/RB
expressed/VBN
./.
====================
Using/VBG
the/DT
technology/NN
of/IN
next-generation/NN
sequencing/NN
,/,
it/PRP
is/VBZ
expected/VBN
that/DT
more/RBR
causal/JJ
,/,
rare/JJ
variants/NNS
will/MD
be/VB
identified/VBN
./.
====================
This/DT
genetic/JJ
information/NN
would/MD
ultimately/RB
improve/VBP
our/PRP$
prediction/NN
of/IN
GDM/NN
and/CC
future/JJ
T2DM/NN
./.
====================
In/IN
addition/NN
,/,
we/PRP
hope/VBP
that/DT
personalized/VBD
genomic/JJ
medicine/NN
could/MD
be/VB
available/JJ
using/VBG
the/DT
advances/NNS
in/IN
the/DT
genetics/NNS
of/IN
GDM/NN
and/CC
T2DM/NN
./.
====================
Comparison/NN
of/IN
risk/NN
allele/NN
frequencies/NNS
of/IN
known/JJ
type/NN
2/CD
diabetes/VBZ
mellitus/NN
(/(
T2DM/NN
)/)
genetic/JJ
variants/NNS
among/IN
a/DT
control/JJ
group/NN
(/(
n/NN
=/JJ
632/CD
,/,
men/NNS
:/:
women/NNS
=/JJ
287/CD
:/:
345/CD
)/)
,/,
T2DM/NN
group/NN
(/(
n/NN
=/JJ
761/CD
,/,
men/NNS
:/:
women/NNS
=/JJ
354/CD
:/:
407/CD
)/)
,/,
and/CC
gestational/JJ
diabetes/VBZ
mellitus/NN
(/(
GDM/NN
)/)
group/NN
(/(
n/NN
=/JJ
869/CD
)/)
in/IN
Koreans/NNS
./.
====================
There/EX
is/VBZ
an/DT
increasing/VBG
trend/NN
of/IN
risk/NN
allele/NN
frequencies/NNS
from/IN
controls/NNS
to/TO
T2DM/NN
and/CC
from/IN
T2DM/NN
to/TO
GDM/NN
./.
====================
The/DT
odds/NNS
ratio/NN
(/(
OR/NN
)/)
and/CC
95/CD
%/NN
confidence/NN
interval/JJ
of/IN
the/DT
risk/NN
variants/NNS
for/IN
risk/NN
of/IN
T2DM/NN
and/CC
GDM/NN
are/VBP
shown/VBN
above/IN
the/DT
bars/NNS
./.
====================
Gestational/JJ
diabetes/NNS
mellitus/NN
(/(
GDM/NN
)/)
and/CC
type/NN
2/CD
diabetes/NNS
mellitus/NN
(/(
T2DM/NN
)/)
have/VBP
similar/JJ
pathophysiologies/NNS
of/IN
impaired/JJ
compensation/NN
of/IN
insulin/NN
secretion/NN
in/IN
the/DT
face/NN
of/IN
increased/VBN
insulin/NN
resistance/NN
./.
====================
GDM/NN
women/NNS
have/VBP
increased/VBN
familial/JJ
clustering/NN
of/IN
T2DM/NN
and/CC
are/VBP
at/IN
high/JJ
risk/NN
of/IN
developing/VBG
T2DM/NN
./.
====================
Using/VBG
genetic/JJ
association/NN
studies/NNS
,/,
it/PRP
has/VBZ
been/VBN
shown/VBN
that/IN
GDM/NN
and/CC
T2DM/NN
share/VBP
similar/JJ
genetic/JJ
backgrounds/NNS
,/,
at/IN
least/JJS
in/IN
part/NN
./.
====================
